These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 35892474)

  • 1. Economic Evaluation of Newborn Screening for Severe Combined Immunodeficiency.
    Shih STF; Keller E; Wiley V; Wong M; Farrar MA; Chambers GM
    Int J Neonatal Screen; 2022 Jul; 8(3):. PubMed ID: 35892474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modelling the Cost-Effectiveness and Budget Impact of a Newborn Screening Program for Spinal Muscular Atrophy and Severe Combined Immunodeficiency.
    Shih STF; Keller E; Wiley V; Farrar MA; Wong M; Chambers GM
    Int J Neonatal Screen; 2022 Jul; 8(3):. PubMed ID: 35892475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Markov model to analyze cost-effectiveness of screening for severe combined immunodeficiency (SCID).
    Chan K; Davis J; Pai SY; Bonilla FA; Puck JM; Apkon M
    Mol Genet Metab; 2011 Nov; 104(3):383-9. PubMed ID: 21810544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
    Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
    Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
    Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
    Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel as Second-line or Later Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
    Choe JH; Abdel-Azim H; Padula WV; Abou-El-Enein M
    JAMA Netw Open; 2022 Dec; 5(12):e2245956. PubMed ID: 36520440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost Utility of Lifelong Immunoglobulin Replacement Therapy vs Hematopoietic Stem Cell Transplant to Treat Agammaglobulinemia.
    Sun D; Heimall JR; Greenhawt MJ; Bunin NJ; Shaker MS; Romberg N
    JAMA Pediatr; 2022 Feb; 176(2):176-184. PubMed ID: 34779842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Newborn screening for spinal muscular atrophy with disease-modifying therapies: a cost-effectiveness analysis.
    Shih ST; Farrar MA; Wiley V; Chambers G
    J Neurol Neurosurg Psychiatry; 2021 Dec; 92(12):1296-1304. PubMed ID: 34321343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Economic Evaluation of Australia's Newborn Hearing Screening Program: A Within-Study Cost-Effectiveness Analysis.
    Sharma R; Gu Y; Sinha K; Ching TYC; Marnane V; Gold L; Wake M; Wang J; Parkinson B
    Ear Hear; 2022; 43(3):972-983. PubMed ID: 34772837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is Reconstruction of Unstable Midfoot Charcot Neuroarthropathy Cost Effective from a US Payer's Perspective?
    Albright RH; Joseph RM; Wukich DK; Armstrong DG; Fleischer AE
    Clin Orthop Relat Res; 2020 Dec; 478(12):2869-2888. PubMed ID: 32694315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States.
    Shah BD; Smith NJ; Feng C; Jeyakumar S; Castaigne JG; Faghmous I; Masouleh BK; Malone DC; Bishop MR
    Adv Ther; 2022 Aug; 39(8):3678-3695. PubMed ID: 35727476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Cost-Effectiveness Analysis of Newborn Screening for Severe Combined Immunodeficiency in the UK.
    Bessey A; Chilcott J; Leaviss J; de la Cruz C; Wong R
    Int J Neonatal Screen; 2019 Sep; 5(3):28. PubMed ID: 33072987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. International Cost-Effectiveness Analysis of Durvalumab in Stage III Non-Small Cell Lung Cancer.
    Kareff SA; Han S; Haaland B; Jani CJ; Kohli R; Aguiar PN; Huang Y; Soo RA; Rodríguez-Perez Á; García-Foncillas J; Dómine M; de Lima Lopes G
    JAMA Netw Open; 2024 May; 7(5):e2413938. PubMed ID: 38814640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of home-based screening of the general population for albuminuria to prevent progression of cardiovascular and kidney disease.
    Pouwels XGLV; van Mil D; Kieneker LM; Boersma C; van Etten RW; Evers-Roeten B; Heerspink HJL; Hemmelder MH; Langelaan MLP; Thelen MHM; Gansevoort RT; Koffijberg H
    EClinicalMedicine; 2024 Feb; 68():102414. PubMed ID: 38299045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined population genomic screening for three high-risk conditions in Australia: a modelling study.
    Lacaze P; Marquina C; Tiller J; Brotchie A; Kang YJ; Merritt MA; Green RC; Watts GF; Nowak KJ; Manchanda R; Canfell K; James P; Winship I; McNeil JJ; Ademi Z
    EClinicalMedicine; 2023 Dec; 66():102297. PubMed ID: 38192593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of newborn screening for severe combined immunodeficiency.
    Van der Ploeg CPB; Blom M; Bredius RGM; van der Burg M; Schielen PCJI; Verkerk PH; Van den Akker-van Marle ME
    Eur J Pediatr; 2019 May; 178(5):721-729. PubMed ID: 30805731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of a population-based AAA screening program for men over 65 years old in Iran.
    Daroudi R; Shafe O; Moosavi J; Salimi J; Bayazidi Y; Zafarghandi MR; Maleki M; Moini M; Farshidmehr P; Sadeghipour P
    Cost Eff Resour Alloc; 2021 May; 19(1):29. PubMed ID: 33985531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of system-level mental health strategies for young people in the Australian Capital Territory: a dynamic simulation modelling study.
    Crosland P; Ho N; Hosseini SH; Vacher C; Skinner A; Natsky AN; Rosenberg S; Hasudungan R; Huntley S; Song YJC; Lee GY; Marshall DA; Occhipinti JA; Hickie IB
    Lancet Psychiatry; 2024 Feb; 11(2):123-133. PubMed ID: 38245017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of cervical length screening and progesterone treatment to prevent spontaneous preterm delivery in Sweden.
    Wikström T; Kuusela P; Jacobsson B; Hagberg H; Lindgren P; Svensson M; Wennerholm UB; Valentin L
    Ultrasound Obstet Gynecol; 2022 Jun; 59(6):778-792. PubMed ID: 35195310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.